HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER
Clinical trials for HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER explained in plain language.
Never miss a new study
Get alerted when new HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER trials appear
Sign up with your email to follow new studies for HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New bladder cancer drug offers hope for avoiding bladder removal
Disease control Not yet recruitingThis study tests a new drug called HS-10566 in people with high-risk bladder cancer that hasn't spread into the muscle wall. It is for those who cannot have or choose not to have their bladder removed. The study has two parts: first finding the best dose, then checking how well i…
Matched conditions: HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER
Phase: PHASE1, PHASE2 • Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 20, 2026 11:55 UTC
-
New bladder cancer drug shows promise in early trial
Disease control Not yet recruitingThis early-phase study tests a new drug called JL19001, given alone or with a standard therapy (BCG), for people with high-risk non-muscle invasive bladder cancer. The main goals are to check safety, find the best dose, and see how the body responds. About 18 adults will take par…
Matched conditions: HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER
Phase: PHASE1 • Sponsor: Jecho Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated May 19, 2026 11:59 UTC
-
New hope for bladder cancer: radiotherapy may beat standard immunotherapy
Disease control Not yet recruitingThis study tests whether a combination of radiotherapy and a drug that makes cancer cells more sensitive to radiation works better than the current standard treatment (BCG) for people with a high-risk type of bladder cancer that hasn't invaded the muscle. About 328 participants w…
Matched conditions: HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER
Phase: PHASE3 • Sponsor: The Christie NHS Foundation Trust • Aim: Disease control
Last updated May 11, 2026 20:52 UTC